Market news

RenovoRx (NASDAQ:RNXT) will use its H. C.

MOUNTAIN VIEW, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York P

MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it has received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq

Detailed price information for Renovorx Inc (RNXT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Renovorx Inc (RNXT-Q) from The Globe and Mail including charting and trades.

RenovoRx (NASDAQ:RNXT) executives and physician speakers discussed the treatment landscape for locally advanced pancreatic cancer, the company’s Trans-Arterial Micro-Perfusion, or TAMP, platform, and commercialization progress for its RenovoCath delivery device during a webinar hosted by JonesTradin

RenovoRx Inc (RNXT) reports a 115% year-over-year revenue surge, driven by commercial adoption and full enrollment in its pivotal TIGERPAC trial.

Moby summary of RenovoRx, Inc.'s Q2 2026 earnings call

RenovoRx (NASDAQ:RNXT) reported record second-quarter revenue as it expanded its commercial cancer-center network and advanced its clinical program for locally advanced pancreatic cancer. For the quarter ended June 30, 2026, the company generated revenue of $909,000, up approximately 61% from $563,

Detailed price information for Renovorx Inc (RNXT-Q) from The Globe and Mail including charting and trades.

RenovoRx (RNXT) delivered earnings and revenue surprises of +37.50% and +25.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Motley Fool Press Release.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

RenovoRx, Inc. (NASDAQ:RNXT) announced Tuesday that it has completed patient enrollment for its Phase 3 TIGeR-PaC study of its targeted drug delivery platform for locally advanced pancreatic cancer (LAPC). The U.S. Food and Drug Administration (FDA)-cleared RenovoCath to isolate blood flow and deliver fluids within the peripheral vascular system, as well as for temporary vessel occlusion during procedures such as chemotherapeutic drug infusion. RenovoRx is evaluating its novel drug-device combin

RenovoRx finishes Phase 3 TIGeR-PaC trial enrollment for locally advanced pancreatic cancer, expecting topline data in H2 2027.

Hernando Salcedo was diagnosed with Stage 3 pancreatic cancer after mild symptoms. Chemotherapy made him feel worse than before his diagnosis.

Detailed price information for Renovorx Inc (RNXT-Q) from The Globe and Mail including charting and trades.